Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10017771HBVENSG00000171557.17protein_codingFGGNoNo2266P02679
TVIS10017828HBVENSG00000171557.17protein_codingFGGNoNo2266P02679
TVIS10005016HBVENSG00000171557.17protein_codingFGGNoNo2266P02679
TVIS10005017HBVENSG00000171557.17protein_codingFGGNoNo2266P02679
TVIS10020896HBVENSG00000171557.17protein_codingFGGNoNo2266P02679
TVIS10029821HBVENSG00000171557.17protein_codingFGGNoNo2266P02679
TVIS10024869HBVENSG00000171557.17protein_codingFGGNoNo2266P02679
TVIS10019019HBVENSG00000171557.17protein_codingFGGNoNo2266P02679
TVIS10048685HBVENSG00000171557.17protein_codingFGGNoNo2266P02679
TVIS10046097HBVENSG00000171557.17protein_codingFGGNoNo2266P02679
TCGA Plot Options
Drug Information
GeneFGG
DrugBank IDDB00009
Drug NameAlteplase
Target IDBE0002092
UniProt IDP02679
Regulation Typebinder
PubMed IDs18673235; 17963464; 22248305
CitationsLongstaff C, Williams S, Thelwell C: Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23.@@Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70.@@Acheampong P, Ford GA: Pharmacokinetics of alteplase in the treatment of ischaemic stroke. Expert Opin Drug Metab Toxicol. 2012 Feb;8(2):271-81. doi: 10.1517/17425255.2012.652615. Epub 2012 Jan 17.
GroupsApproved; Investigational
Direct ClassificationPeptides
SMILES
PathwaysAlteplase Action Pathway
PharmGKBPA164776730
ChEMBLCHEMBL1201593